Best-value medicine - Teriparatide

The Medicines Management Programme recommends Movymia®Sondelbay® and Tetridar® as the best-value medicines (BVMs) for teriparatide on the High Tech Arrangement.

Clinicians should give due consideration to prescribing Movymia®, Sondelbay® or Tetridar® when issuing a prescription for teriparatide on the High Tech Arrangement. Implementation of this recommendation will lead to significant savings for the health service.

Copies of the relevant MMP Evaluation Reports are available in the Related Files section below.

Since 1 March 2023, it is HSE policy that all adult patients who are commencing treatment with teriparatide should be prescribed one of the recommended BVMs for teriparatide.

Resources to support prescribing of the best-value medicines, Movymia®, Sondelbay® and Tetridar®, are located in the Related Files section below:

  • BVM Teriparatide Communication to Prescribers February 2023
  • BVM Teriparatide Questions and Answers for Healthcare Professionals
  • BVM Reimbursement of Teriparatide Q and A for Healthcare Professionals April 2024
  • BVM Teriparatide Patient Information April 2024
  • BVM Product Information Sheets for Movymia®, Sondelbay® and Tetridar®
  • BVM Teriparatide Patient and Clinic Support Services – contains information on and contact details for patient support programmes for Movymia®, Sondelbay® and Tetridar®
  • Templates for switching leaflets for Movymia®, Sondelbay® and Tetridar®
  • Templates for switching letters for Movymia®, Sondelbay® and Tetridar®